# Indian Pharmaceutical Market (IPM)

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/indian-pharmaceutical-market-ipm
Canonical HTML page: https://getbiobrief.com/entity/indian-pharmaceutical-market-ipm

## Recent coverage (1 stories)

### Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr
2026-08-09 18:00:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Indian pharmaceutical market expanded 12.1% by value in July 2026, but unit growth inched up only 1.6%, revealing a market shifting to high-value, specialty therapies. Anti-neoplastics and anti-diabetics led therapy-area growth, while Eli Lilly’s Mounjaro captured more than half of the diabetes segment with an 880% sales surge. For biotech and pharma firms, the data underscores the imperative to invest in innovation and patient access strategies.
Full story: https://getbiobrief.com/story/indian-pharma-market-growth-july-2026-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.